<DOC>
	<DOCNO>NCT01345279</DOCNO>
	<brief_summary>Indirect comparison perform use data GOG-0179 versus GOG-0169 permit comparison topotecan combination cisplatin versus cisplatin plus paclitaxel via common comparator cisplatin monotherapy . Both GOG-0179 GOG-0169 conduct patient stage IVB , recurrent persistent carcinoma cervix , difference respective study population . Patients prior chemotherapy eligible GOG-0179 ineligible GOG-0169 ( except chemotherapy use radiation sensitisation ) . Fewer patient receive chemotherapy radiosensitiser GOG-0169 ( 27 % ) GOG-0179 ( ~60 % ) patient unevenly distribute treatment arm GOG-0169 . In addition , proportion patient receive cisplatin radiosensitiser GOG-0169 unknown . For reason , limitation associate indirect meta-analysis .</brief_summary>
	<brief_title>Indirect Comparison Topotecan Cervical Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>randomise clinical trial , systematic review metaanalyses treatment topotecan platinumbased single combination regimen female patient race cancer cervix recurrent radiotherapy stage IVB disease</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>